GordonMD Global Investments LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002039349

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025

Q3 2026 · 14 positions · Total reported value $166.47M · Top-10 concentration 85.7% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.7% · 2 new · 6 cut · 4 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.1% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -14.1% · vs SPY -16.2% · Prev Value $206.66M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -10.2% · vs SPY -12.4% · Latest Value $166.47M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, GordonMD Global Investments LP disclosed 14 equity positions with a combined reported value of $166.47M. The filing implies a focused portfolio: its ten largest positions account for 85.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PYXS ($36.21M), KYTX ($30.74M), TEVA ($15.03M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+2.3pp) and away from Other (-2.3pp).

Versus the prior quarter, GordonMD Global Investments LP opened 2 new positions, trimmed 6 and fully exited 4, a turnover rate of 66.7% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q3 2026 were TNGX ($9.02M), VNDA ($8.97M).

Of the 4 positions fully exited versus the prior quarter, the largest were RARE ($9.65M), SION ($5.98M), CRNX ($4.75M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • TNGX TANGO THERAPEUTICS INC · $9.02M
  • VNDA VANDA PHARMACEUTICALS INC · $8.97M

Fully Exited (vs previous quarter)

  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $9.65M
  • SION SIONNA THERAPEUTICS INC · prev qtr: $5.98M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $4.75M
  • INSM INSMED INC · prev qtr: $3.05M

Insider Transactions (Form 4)

Latest GordonMD Global Investments LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-01 Buy Pyxis Oncology, Inc. 5,517,000 — SEC filing

All insider transactions →

Fund Profile

GordonMD Global Investments LP is an SEC-registered 13F filer based in Beverly Hills, CA, United States. As of Q3 2026 it reported 14 US equity positions with a combined value of $166.47M. HoldingsHub carries 4 quarters of its filings (Q4 2025–Q3 2026).

Firm Snapshot

  • Headquarters: BEVERLY HILLS, CA, United States
  • SEC registration: 801-128434 (status: Approved), registered 2023-08-01
  • Regulatory AUM (Form ADV): $322.27M as of 2026-03-26
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 1 hedge funds

Portfolio Structure

  • 14 positions · $166.47M reported value (Q3 2026)
  • Top 10 holdings = 85.7% of reported value
  • Largest position: PYXS (PYXIS ONCOLOGY INC) at 21.8%
  • Average position size: $11.89M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 3 added, 6 reduced, 4 exited
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is aggressively increasing exposure to high-growth oncology/biotech names (PYXS, TNGX, VNDA) while trimming positions in larger-cap pharma (TEVA, VIR) and medical devices (BLCO), signaling a bullish view on innovative healthcare but reduced confidence in established players. 2. Key moves: - Added: PYXS (+55.0% shares), KYTX (+6.5% shares). - Reduced: TEVA (-84.2% shares), VIR (-40.6% shares), BLCO (-17.1% shares). - New positions: TNGX, VNDA. 3. Portfolio structure: Highly active, concentrated (top 10 = 81.25%), and heavily biased toward Health Care (100%), with a preference for small/mid-cap biotech/oncology stocks, indicating high risk appetite. 4. Per-holding one-liner: - PYXS: PYXIS Oncology (cancer therapies). - KYTX: KYVERNA Therapeutics (autoimmune diseases). - TEVA: Teva Pharmaceuticals (generic drugs). - CLDX: Celldex Therapeutics (cancer vaccines). - TNGX: Tango Therapeutics (cancer genomics). - VIR: VIR Biotechnology (infectious diseases). - VNDA: Vanda Pharmaceuticals (CNS disorders). - ALLO: Allogene Therapeutics (cell therapy). - BLCO: Bausch + Lomb (eye health). - EDIT: Editas Medicine (gene editing). 5. Style summary: Concentrated biotech/oncology fund doubling down on high-growth names while paring back established healthcare names.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 05:54

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 15.54M $36.21M 21.75%
Form 4 · 1 →
21.75%
Add
2 4.52M $30.74M 18.47%
18.47%
Add
3 379.52K $15.03M 9.03%
9.03%
Reduce
4 279.72K $9.07M 5.45%
5.45%
Hold
5 1.85M $9.02M 5.42%
5.42%
New
6 803.55K $8.98M 5.40%
5.40%
Reduce
7 450.00K $8.97M 5.39%
5.39%
New
8 5.30M $8.48M 5.09%
5.09%
Hold
9 475.47K $8.08M 4.86%
4.86%
Reduce
10 3.13M $8.04M 4.83%
4.83%
Hold
11 51.08K $6.20M 3.72%
3.72%
Add
12 248.00K $6.19M 3.72%
3.72%
Reduce
13 14.51K $6.12M 3.67%
3.67%
Reduce
14 110.50K $5.34M 3.21%
3.21%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 80% R 80% F1 80% (modelled on 2026-Q2; 8/10 hit)

Low-confidence forecast This fund replaces about 27% of its Top-10 each quarter and backtests at F1 75% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (2 quarters)

Avg precision 75% · recall 75% · F1 75% · avg rank error 3.0 · Top-10 turnover 27%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2026-Q2 70% 70% 70% KYTX · TSHA · VIR · BLCO · AMGN · SRRK · TEVA · PYXS · RARE · SION KYTX · PYXS · TSHA · TEVA · VIR · ALLO · CLDX · EDIT · RARE · BLCO
2026-Q3 ★ 80% 80% 80% KYTX · PYXS · TSHA · TEVA · VIR · ALLO · CLDX · EDIT · RARE · BLCO PYXS · KYTX · TEVA · CLDX · TNGX · VIR · VNDA · ALLO · BLCO · EDIT

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings4 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-3.17%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+13.85%vs benchmark
Barra annualised vol52.8%Model estimate
Realised vol48.1%Annualised in window
Weighted beta1.21Raw exposure
Factor / specific risk37% / 63%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16GordonMD Global Investments LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-3.17%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+13.85%Portfolio − benchmark
Arithmetic return sum-1.73%Difference vs compounded is the cross term
Weighted raw beta1.21Weighted holding betas
Realised volatility (annualised)48.10%Daily returns in window
Barra model volatility (annualised)52.80%Factor + specific
Factor share of variance36.7%Barra factors
Specific share of variance63.3%Stock residuals
Reported value$26.7M13F long US equity

2. Return attribution

The -1.73% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -4.32% -249.7%
Momentum & Growth 3 -7.60% -439.5%
Volatility & Tail Risk 7 -2.31% -133.8%
Industry 12 +6.98% 403.9%
Specific 1 +5.52% 319.1%
Return attribution (style + industry, %)-10.7-5.3+0.0+5.3+10.7Max Drawdown-0.81Amihud Illiquidity-0.87Leverage (Downside Vol)-1.21Skewness+1.33Beta+1.57Growth-1.62Non-linear Size+2.21Size+2.42Mid Cap-3.77Turnover-4.53Residual Volatility+6.30Momentum-6.33Health Care+6.98Historical Volatility-9.89
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +6.98% +6.98% 403.9%
Residual Volatility Style +1.91 +3.29% +6.30% 364.3%
Specific Specific — — +5.52% 319.1%
Size Style -1.24 -1.95% +2.42% 140.1%
Non-linear Size Style +2.19 +1.01% +2.21% 127.7%
Beta Style +0.35 +4.44% +1.57% 90.7%
Skewness Style -0.30 -4.39% +1.33% 77.0%
Kurtosis Style +0.05 +7.51% +0.39% 22.8%
Short-term Reversal Style +0.40 +0.87% +0.35% 20.1%
Liquidity Style +0.63 +0.36% +0.23% 13.1%
Max Drawdown Style +0.46 -1.76% -0.81% -47.0%
Amihud Illiquidity Style +1.95 -0.45% -0.87% -50.3%
Leverage (Downside Vol) Style +0.70 -1.71% -1.21% -69.7%
Growth Style -0.93 +1.75% -1.62% -93.5%
Mid Cap Style +1.95 -1.94% -3.77% -218.3%
Turnover Style +0.94 -4.80% -4.53% -262.0%
Momentum Style +1.58 -4.00% -6.33% -366.1%
Historical Volatility Style +0.71 -14.00% -9.89% -571.9%

3. Risk attribution

Annualised volatility is 52.80%; factor risk explains 36.7% of variance and specific risk 63.3%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-68.4-34.2+0.0+34.2+68.4Growth-0.74Non-linear Size+0.77Liquidity+0.86Turnover+0.86Amihud Illiquidity+1.18Max Drawdown+1.18Beta+2.38Historical Volatility+2.43Size+2.80Momentum+4.13Mid Cap+4.91Residual Volatility+5.23Health Care+9.87Specific+63.29
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 63.3% +33.42% 33.4%
Health Care Industry +1.00 9.9% +5.21% 5.2%
Residual Volatility Style +1.91 5.2% +2.76% 2.8%
Mid Cap Style +1.95 4.9% +2.59% 2.6%
Momentum Style +1.58 4.1% +2.18% 2.2%
Size Style -1.24 2.8% +1.48% 1.5%
Historical Volatility Style +0.71 2.4% +1.28% 1.3%
Beta Style +0.35 2.4% +1.26% 1.3%
Amihud Illiquidity Style +1.95 1.2% +0.62% 0.6%
Max Drawdown Style +0.46 1.2% +0.62% 0.6%
Liquidity Style +0.63 0.9% +0.46% 0.5%
Turnover Style +0.94 0.9% +0.46% 0.5%
Non-linear Size Style +2.19 0.8% +0.41% 0.4%
Leverage (Downside Vol) Style +0.70 0.7% +0.38% 0.4%
Growth Style -0.93 -0.7% -0.39% -0.4%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.6-0.60.51.52.5Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.24 +2.10 -3.34
Non-linear Size +2.19 +1.68 +0.51
Mid Cap +1.95 +0.13 +1.82
Beta +0.35 +1.29 -0.94
Momentum +1.58 +0.72 +0.87
Short-term Reversal +0.40 -0.64 +1.04
Residual Volatility +1.91 -0.40 +2.31
Historical Volatility +0.71 +0.86 -0.15
Liquidity +0.64 +0.11 +0.52
Amihud Illiquidity +1.95 +1.16 +0.80
Turnover +0.94 +0.21 +0.74
Growth -0.93 +0.58 -1.51
Leverage (Downside Vol) +0.70 +0.14 +0.56
Skewness -0.30 +0.24 -0.54
Kurtosis +0.05 +0.21 -0.16
Max Drawdown +0.46 -0.08 +0.55

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -4.26% +8.29% +24.98% -0.22% -12.33% -4.41%
Total +23.98% +15.62% -28.17% +11.44%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
TNGX TANGO THERAPEUTICS INC Health Care 33.83% -3.13% -1.06% New
TSHA TAYSHA GENE THERAPIES INC Health Care 23.20% -16.63% -3.86% Reduce
AMGN AMGEN INC Health Care 22.94% +9.68% +2.22% Reduce
SRRK SCHOLAR ROCK HLDG CORP Health Care 20.02% -7.82% -1.57% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 AMGN Health Care 22.94% +9.68% +2.22%
2 TNGX Health Care 33.83% -3.13% -1.06%
3 SRRK Health Care 20.02% -7.82% -1.57%
4 TSHA Health Care 23.20% -16.63% -3.86%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -3.17%, versus -17.01% for the QQQ synthetic benchmark — an excess of +13.85%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +6.98%, Residual Volatility +6.30%, Size +2.42%; the largest drags came from Historical Volatility -9.89%, Momentum -6.33%, Turnover -4.53%. Specific (stock-level) return contributed +5.52%.
  3. Risk attribution: Barra model volatility is 52.80% annualised; factor risk explains 37% of variance and specific risk 63%. The largest factor risk sources are Health Care 9.9%, Residual Volatility 5.2%, Mid Cap 4.9%.
  4. Style tilt: size -1.24, momentum +1.58, volatility +0.71, liquidity +0.64; the weighted raw beta is 1.21. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.62% and interaction -28.17%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did GordonMD Global Investments LP buy in 2026-Q3?

In its 2026-Q3 13F filing, GordonMD Global Investments LP reported 14 equity positions worth $166.47M in aggregate; its largest disclosed positions were PYXS ($36.21M), KYTX ($30.74M), TEVA ($15.03M).

How large is GordonMD Global Investments LP's portfolio?

GordonMD Global Investments LP reported $166.47M of long equity holdings across 14 positions as of 2026-Q3. Top-10 holdings account for 85.7% of reported value.

What is GordonMD Global Investments LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/gordonmd-global-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →